Form 4 for SLXN Silexion Therapeutics Corp
Accepted 2026-06-08 16:05:04 ET · period of report 2026-06-04 · accession 0001178913-26-003134 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-08 16:05 | 2026-06-04 | SLXN | Horenshtein Hadar Mirit | CFO, Sec | A - Grant | $0.00 | +7,500 | 12.5K | +150% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-06-04 | A | A | 7,500 | $0.00 | 12,515 | D | — | — | (F1) The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on February 23, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 50,146 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 5,015 ordinary shares, par value $0.135, prior to the grant reported in this Form 4). (F2) The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's service as an officer of the Issuer. The grant was approved by the Issuer's board of directors. |